The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as ...

mNexspike becomes Moderna’s third FDA-approved product, joining Spikevax (original COVID-19 vaccine) and mResvia (RSV vaccine). Spikevax is approved/authorized for use by the FDA in individuals ...

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.. The new vaccine is indicated for active immunization to prevent COVID-19 caused ...

Moderna’s mNEXSPIKE (mRNA-1283), a new COVID-19 vaccine, received FDA approval based on Phase III trial data showing higher relative vaccine efficacy than Spikevax. The vaccine will be available for ...

FDA Approves Moderna’s mNEXSPIKE for High-Risk Populations: Moderna’s next-generation COVID-19 vaccine, mNEXSPIKE (mRNA-1283), has received FDA approval for adults aged 65 years and older and ...

mNexspike becomes Moderna’s third FDA-approved product, joining Spikevax (original COVID-19 vaccine) and mResvia (RSV vaccine). Spikevax is approved/authorized for use by the FDA in individuals ...

Rep. Marjorie Taylor Greene, R-Ga., slammed the U.S. Food and Drug Administration's move to give the green light to Moderna's mNEXSPIKE COVID-19 vaccine. "Not MAHA at all!!!," the congresswoman ...

Moderna MRNA announced the FDA approval for mRNA-1283, its next-generation refrigerator-stable COVID-19 vaccine, though for a label narrower than initially targeted. The vaccine will be marketed under ...

The Food and Drug Administration has approved Moderna's mNEXSPIKE (mRNA-1283), a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years with at ...